Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 10/20 | 1.00 |
| ▸ | GPBAR1 | Q8TDU6 | 4/20 | 1.00 |
| ▸ | CYSLTR2 | Q9NS75 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.65 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | MAPT | P10636 | 1/20 | 0.65 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.65 |
| ▸ | TSHR | P16473 | 1/20 | 0.65 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.65 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.65 |
| ▸ | THPO | P40225 | 1/20 | 0.65 |
| ▸ | BLM | P54132 | 1/20 | 0.65 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30444017 | 1.00 | CYSLTR1 (1.00) | CYSLTR1GPBAR1CYSLTR2KDM4EMEN1 | |
| Hydrochloric Acid SCHEMBL7006935 | 0.99 | CYSLTR1 (0.97) | CYSLTR1GPBAR1CYSLTR2KDM4EMEN1 | |
| SCHEMBL7716691 | 0.94 | CYSLTR1 (0.88) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7715799 | 0.93 | CYSLTR1 (0.86) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7010090 | 0.91 | CYSLTR1 (0.84) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL26771313 | 0.90 | CYSLTR1 (0.80) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7006928 | 0.90 | CYSLTR1 (0.81) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL10484526 | 0.90 | CYSLTR1 (0.81) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL202997 | 0.90 | CYSLTR1 (0.81) | CYSLTR1GPBAR1CYSLTR2 | |
| SCHEMBL7801672 | 0.89 | GPBAR1 (0.85) | CYSLTR1GPBAR1CYSLTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | PREC BIO THERAPEUTICS S R L (IT) | 2023-11-09 | — | — | US | disclosed |
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | PREC BIO THERAPEUTICS S R L (IT) | 2023-11-09 | — | — | US | disclosed |
| CN-116323560-A | Quinoline compounds as selective and/or dual modulators of bile acid receptors and leukotriene cysteinyl receptors | 精密生物治疗有限责任公司 | 2023-06-23 | — | — | CN | disclosed |
| EP-4192815-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | Precision Bio-Therapeutics S.r.l. (IT) | 2023-06-14 | — | — | EP | disclosed |
| EP-2607348-B1 | Plasminogen Activator Inhibitor-1 Inhibitor | RENASCIENCE INC (JP) | 2021-03-17 | — | — | EP | disclosed |
| CN-102378753-B | Plasminogen activator-1 inhibitor | RENASCIENCE Co.,Ltd. (JP) | 2016-03-02 | — | — | CN | disclosed |
| CN-102491969-B | Heteroaromatic quinoline compounds and the purposes as PDE10 inhibitor thereof | PFIZER PRODUCTS INC. (US) | 2015-08-19 | — | — | CN | disclosed |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | RENASCIENCE CO LTD (JP) | 2014-10-02 | — | — | US | disclosed |
| US-8785473-B2 | Plasminogen activator inhibitor-1 inhibitor | RENASCIENCE CO., LTD. (JP) | 2014-07-22 | — | — | US | disclosed |
| EP-2607348-A2 | Plasminogen Activator Inhibitor-1 Inhibitor | Renascience CO., LTD. (JP) | 2013-06-26 | — | — | EP | disclosed |
| EP-0309541-B1 | SULFONYLCARBOXAMIDES | AMERICAN HOME PRODUCTS CORPORATION (US) | 1992-01-02 | — | — | EP | disclosed |
| US-5059610-A | QUINOLINE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF LEUKOTRIENE D4 | RHONE-POULENC RORER PHARMACEUTICALS INC. (US) | 1991-10-22 | — | — | US | disclosed |
| US-4920132-A | Quinoline derivatives and use thereof as antagonists of leukotriene D4 | RORER PHARMACEUTICAL CORP. (US) | 1990-04-24 | — | — | US | disclosed |
| US-4839369-A | ANTIINFLAMMATORY AGENTS; ANTIALLERGENS | RORER PHARMACEUTICAL CORPORATION (US) | 1989-06-13 | — | — | US | disclosed |
| WO-1989004305-A1 | QUINOLINE DERIVATIVES AS ANTAGONISTS OF LEUKOTRIENE D4 | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-05-18 | — | — | WO | disclosed |
| EP-0315399-A2 | Quinoline derivatives, their use in the treatment of hypersensitive ailments and a pharmaceutical composition containing the same | RHONE-POULENC RORER INTERNATIONAL (HOLDINGS) INC. (US) | 1989-05-10 | — | — | EP | disclosed |
| US-4728668-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1988-03-01 | — | — | US | disclosed |
| US-4725619-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORPORATION (US) | 1988-02-16 | — | — | US | disclosed |
| US-4631287-A | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive ailments | USV PHARMACEUTICAL CORP. (US) | 1986-12-23 | — | — | US | disclosed |
| EP-0200101-A2 | Aryl and heteroaryl ethers as agents for the treatment of hypersensitive aliments | USV PHARMACEUTICAL CORPORATION (US) | 1986-11-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357159-A1 | QUINOLINE COMPOUNDS AS SELECTIVE AND/OR DUAL MODULATORS OF BILE ACID RECEPTORS AND LEUKOTRIENE CYSTEINYL RECEPTORS | GPBAR1, CYSLTR1, CYSLTR2 | CYSLTR1 2/4885GPBAR1 1/4885CYSLTR2 3/4885 |
| US-20140296256-A1 | PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR | SERPINE1, SERPINC1, SERPINB1 | CYSLTR1 856/4885GPBAR1 2224/4885CYSLTR2 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.